title: Effect of body mass index on survival after curative therapy for non-B non-C hepatocellular carcinoma.
abstract: OBJECTIVE
  The impact of obesity on survival after curative treatment for non-B non-C hepatocellular carcinoma (NBNC-HCC) remains unclear. This study examined the prognostic impact of obesity in patients who received curative therapy for NBNC-HCC.
  
  
  METHODS
  A total of 260 patients with NBNC-HCC who underwent curative therapy were analyzed. They included 116 obese patients (44.6%) with a body mass index (BMI) >25 kg/m² (obesity group) and 144 control patients (55.4%) with a BMI <25 kg/m² (control group). Overall survival (OS) and recurrence-free survival (RFS) rates were compared.
  
  
  RESULTS
  The median observation periods in the obesity and control groups were 3.1 and 3.0 years, respectively. The 1-, 3- and 5-year cumulative OS rates were 93.9%, 77.3% and 56.0% in the obesity group, and 98.8%, 77.3% and 62.1% in the control group, respectively (p = 0.955). The corresponding RFS rates were 74.6%, 28.0% and 19.0% in the obesity group, and 70.0%, 44.3% and 28.9%, in the control group, respectively (p = 0.128). Multivariate analyses identified a serum albumin >4.0 g/dL (hazard ratio [HR], 1.759; 95% confidence interval [CI], 1.007-3.074; p = 0.047) and des-γ-carboxy prothrombin >100 mAU/mL (HR, 0.396; 95% CI, 0.243-0.646; p < 0.001) as independent factors linked to OS. Alkaline phosphatase>300 IU/L (HR, 0.549; 95% CI, 0.367-0.823; p = 0.004) and gamma-glutamyl transferase >100 IU/L (HR, 0.679; 95% CI, 0.471-0.978; p = 0.038) were significant adverse predictors linked to RFS.
  
  
  CONCLUSIONS
  Obesity does not affect survival in patients with NBNC-HCC after curative therapy.
authors.affiliation: Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Japan. h-nishikawa@osaka-med.jrc.or.jp
authors.forename: Hiroki
authors.initials: H
authors.lastname: Nishikawa
authors.forename: Yukio
authors.initials: Y
authors.lastname: Osaki
authors.forename: Haruhiko
authors.initials: H
authors.lastname: Takeda
authors.forename: Azusa
authors.initials: A
authors.lastname: Sakamoto
authors.forename: Sumio
authors.initials: S
authors.lastname: Saito
authors.forename: Norihiro
authors.initials: N
authors.lastname: Nishijima
authors.forename: Akihiro
authors.initials: A
authors.lastname: Nasu
authors.forename: Akira
authors.initials: A
authors.lastname: Arimoto
authors.forename: Ryuichi
authors.initials: R
authors.lastname: Kita
authors.forename: Toru
authors.initials: T
authors.lastname: Kimura
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015992:Body Mass Index; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D015897:Comorbidity; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008113:Liver Neoplasms / Q000150:complications / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009765:Obesity / Q000150:complications* / Q000175:diagnosis / Q000401:mortality; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome